AIM: The aim of this study was to retrospectively assess the haemostatic efficacy of the endoscopic topical use of Ankaferd Blood Stopper (ABS) in the setting of neoplastic GI bleeding. METHODS: The records of 10 patients with neoplastic GI bleeding (7 gastric, 3 rectal) were evaluated retrospectively. Written informed consent regarding the off-label use of ABS as a means of attaining haemostasis had been obtained from all of the patients prior to the procedure. In all patients, ABS was applied topically. Rates of bleeding control and post-procedural complications were documented. RESULTS: Haemostasis was achieved in all patients within seconds of endoscopic application of ABS, with no immediate complications. Seven patients underwent subsequent cancer surgery after a bleeding-free post-procedural period. CONCLUSIONS: ABS as a novel haemostatic agent could have a potential benefit in controlling bleeding from GI tumours. Prospective controlled studies are needed to help establish its efficacy, and perhaps offer a comparison to conventional haemostatic interventions. 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
AIM: The aim of this study was to retrospectively assess the haemostatic efficacy of the endoscopic topical use of Ankaferd Blood Stopper (ABS) in the setting of neoplastic GI bleeding. METHODS: The records of 10 patients with neoplastic GI bleeding (7 gastric, 3 rectal) were evaluated retrospectively. Written informed consent regarding the off-label use of ABS as a means of attaining haemostasis had been obtained from all of the patients prior to the procedure. In all patients, ABS was applied topically. Rates of bleeding control and post-procedural complications were documented. RESULTS: Haemostasis was achieved in all patients within seconds of endoscopic application of ABS, with no immediate complications. Seven patients underwent subsequent cancer surgery after a bleeding-free post-procedural period. CONCLUSIONS:ABS as a novel haemostatic agent could have a potential benefit in controlling bleeding from GI tumours. Prospective controlled studies are needed to help establish its efficacy, and perhaps offer a comparison to conventional haemostatic interventions. 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Authors: Gokhan Gungor; M Hakan Goktepe; Murat Biyik; Ilker Polat; Tuncer Tuna; Huseyin Ataseven; Ali Demir Journal: World J Gastrointest Endosc Date: 2012-12-16
Authors: Yavuz Beyazit; Murat Kekilli; Ibrahim C Haznedaroglu; Ertugrul Kayacetin; Metin Basaranoglu Journal: World J Gastroenterol Date: 2011-09-21 Impact factor: 5.742
Authors: Nesrin Turhan; Hasan Bilgili; Ozge Captug; Mevlut Kurt; Ali Shorbagi; Yavuz Beyazit; Ozlem Kar Kurt; Ali Kosar; Ibrahim Celalettin Haznedaroglu Journal: Afr J Tradit Complement Altern Med Date: 2010-10-02
Authors: Mevlut Kurt; Ibrahim Onal; Meral Akdogan; Murat Kekilli; Mehmet Arhan; Abdurrahim Sayilir; Erkin Oztas; Ibrahim Haznedaroglu Journal: Can J Gastroenterol Date: 2010-06 Impact factor: 3.522
Authors: Mehmet Kelles; M Tayyar Kalcioglu; Emine Samdanci; Erol Selimoglu; Mustafa Iraz; Murat Cem Miman; Ibrahim C Haznedaroglu Journal: Curr Ther Res Clin Exp Date: 2011-10